KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) announced that Patrick Crutcher has been appointed Head of Business Development, Chris Thorn has been appointed interim Chief Financial Officer and Edward Painter has been appointed Head of Communications and Investor Relations.
Martin Shkreli, Chief Executive Officer, said, “We are moving quickly to build a very high quality team focused on optimizing the growth opportunities at KaloBios Pharmaceuticals.”
Patrick Crutcher is also a Founder and Head of Business Development for Turing Pharmaceuticals and was a key member of the business development team at Retrophin. Additionally, Mr. Crutcher was a healthcare consultant focused on private and publicly traded biotechnology companies.
Chris Thorn is also Controller of Turing Pharmaceuticals and his previous experience includes being Controller of Kamdon Corp and Audit Manager with KPMG LLP. Mr. Thorn is a certified public accountant in the State of New York.
Edward Painter is also Head of Communications and Investor Relations with Turing Pharmaceuticals. His experience includes 25 years of working with biopharma investors at numerous investment banks and managing his own investment firm. His career began with Salomon Brothers and Goldman Sachs and was most recently with UBS. (Original Source)
Shares of KaloBios Pharmaceuticals Inc closed yesterday at $30.97, down $3.22 or -9.42%. KBIO has a 1-year high of $45.82 and a 1-year low of $0.44. The stock’s 50-day moving average is $8.33 and its 200-day moving average is $4.41.
KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibody therapeutics for diseases that burdens the society and to patients and their families.